VIA
SGMO

Vantage Investment Advisors’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Vantage Investment Advisors’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$8K Hold
500
– – ﹤0.01% 577
2018
Q2 		$7K Buy
+500
New +$8.31K ﹤0.01% 598

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vantage Investment Advisors's SGMO Position: Q3 2018 in Review

Vantage Investment Advisors held its SANGAMO THERAPEUTICS INC (SGMO) position steady in Q3 2018 at 500 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #577.

Vantage Investment Advisors first reported a position in SGMO in Q2 2018 and has held it in 2 quarters since. 217 funds tracked by Wall St. Rank hold SGMO as of Q3 2018.

  • Vantage Investment Advisors held 500 shares of SANGAMO THERAPEUTICS INC worth $8K as of Q3 2018.
  • Vantage Investment Advisors left its SANGAMO THERAPEUTICS INC share count unchanged in Q3 2018.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of Vantage Investment Advisors's portfolio in Q3 2018, its #577 holding.
  • Vantage Investment Advisors first reported a position in SANGAMO THERAPEUTICS INC in Q2 2018 and has held it in 2 quarters since.
  • 217 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2018.

Based on Vantage Investment Advisors's 13F filing for Q3 2018, filed 9 Nov 2018.